Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries

Autor: Aleksandr M. Faynboym, John Steel, Ramesh R. Bhatt, Li Xu, Richard A. Lerner, Peter Palese, Ryann E. Swale, Angeles Estelles, Raffaella Briante, Pamela K. Foreman, Adam Rubrum, Richard J. Webby, Lawrence Horowitz, Natalia A. Ilyushina, Arun K. Kashyap, Michael Horowitz
Jazyk: angličtina
Rok vydání: 2010
Předmět:
viruses
Reassortment
Antibodies
Viral
medicine.disease_cause
Disease Outbreaks
Mice
Influenza A Virus
H1N1 Subtype
Survivors
lcsh:QH301-705.5
0303 health sciences
education.field_of_study
biology
Antibodies
Monoclonal
virus diseases
3. Good health
Infectious Diseases
Immunology/Antigen Processing and Recognition
Immunotherapy
Biochemistry/Drug Discovery
Antibody
Research Article
Biotechnology
lcsh:Immunologic diseases. Allergy
Immunology
Population
Cross Reactions
Microbiology
Antigenic drift
Virus
Viral Function
03 medical and health sciences
Orthomyxoviridae Infections
Immunology/Immunity to Infections
Virology
Infectious Diseases/Viral Infections
Influenza
Human
Genetics
medicine
Animals
Humans
education
Molecular Biology
030304 developmental biology
Influenza A Virus
H5N1 Subtype
030306 microbiology
Infectious Diseases/Respiratory Infections
Antigenic shift
Influenza A virus subtype H5N1
Disease Models
Animal
lcsh:Biology (General)
Immunology/Immune Response
biology.protein
Parasitology
lcsh:RC581-607
Zdroj: PLoS Pathogens, Vol 6, Iss 7, p e1000990 (2010)
PLoS Pathogens
ISSN: 1553-7374
1553-7366
Popis: Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result, the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is being pursued. Such novel broadly acting antiviral therapies would be less susceptible to virus escape and provide a long lasting solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06) against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1 and 2009 “Swine” H1N1 pandemic influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models of disease. These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population.
Author Summary Influenza viruses constantly challenge our ability to prevent and treat their resulting infection. From a survivor of the H5N1 influenza we have discovered an antibody that is effective against both H5N1 and seasonal H1N1 influenza viruses. Here we show the antibody is effective against 2009 pandemic influenza in a cell culture assay and also in mouse models of disease when given before and even after lethal influenza infection. The present work demonstrates the viability of this particular antibody and the general approach of using antibodies against viral pathogens as opposed to traditional treatments that are losing their efficacy for the prevention and treatment of influenza infection. We conclude the efficacy of this antibody warrants further experimental testing as an alternative therapy for treatment in man.
Databáze: OpenAIRE
Externí odkaz: